Cour Pharmaceuticals Raises $105 Million to Reprogram Immune System
January 31, 2024
Rare Daily Staff
Cour Pharmaceuticals, a clinical-stage company focused on disease modifying therapies designed to induce antigen-speciﬁc tolerance for immune-mediated diseases, raised $105 million in a series A investment round.
Lumira Ventures and Alpha Wave Ventures co-led the financing, with participation from Roche Venture Fund, Pfizer (as part of the Pfizer Breakthrough Growth Initiative), Bristol Myers Squibb, Angelini Ventures, and the JDRF T1D Fund.
“The impressive syndicate of thought-leading investors and prominent strategic investors is a testament to Cour’s platform technology and our paradigm-changing potential for patients impacted by a variety of autoimmune diseases,” said John Puisis, founder and CEO of COUR. “We are excited to have this support as we advance our pipeline and revolutionize antigen-specific immune tolerance while avoiding immune system suppression in our mission to potentially bring to market life changing therapies for patients.”
Cour’s first-in-class therapies are based on a proprietary antigen-specific immune tolerance platform and are designed to reprogram the immune system to address the underlying root cause of immune-mediated diseases. Data from multiple clinical and preclinical programs have demonstrated the ability of Cour’s product candidates to induce antigen-specific immune tolerance and have the potential to treat a wide range of autoimmune and inflammatory diseases.
The company’s clinical pipeline includes product candidates in myasthenia gravis and type 1 diabetes, in addition to having partnered products in celiac disease (with Takeda Pharmaceuticals), and primary biliary cholangitis (with Ironwood Pharmaceuticals).
Proceeds from the financing will enable Cour to advance multiple, wholly owned product candidates that leverage the company’s immune tolerance platform, including phase 2a proof-of-concept clinical studies in myasthenia gravis and Type 1 diabetes, and other pipeline opportunities.
Sign up for updates straight to your inbox.